Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802)

Kazuhiko Yamada; Koichi Azuma; Masafumi Takeshita; Junji Uchino; Chinatsu Nishida; Takayuki Suetsugu; Akira Kondo; Taishi Harada; Hirofumi Eida; Junji Kishimoto; Goki Eriguchi; Koichi Takayama; Yoichi Nakanishi; Kenji Sugio

Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802)

Kazuhiko Yamada, Koichi Azuma, Masafumi Takeshita, Junji Uchino, Chinatsu Nishida, Takayuki Suetsugu, Akira Kondo, Taishi Harada, Hirofumi Eida, Junji Kishimoto, Goki Eriguchi, Koichi Takayama, Yoichi Nakanishi, Kenji Sugio

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Background: As the incidence of lung cancer in the elderly is increasing worldwide, there exists a need to develop a clinically effective, less toxic therapy for this patient population. Although erlotinib has shown proven effectiveness against non-small cell lung cancer (NSCLC), few studies have prospectively investigated its application to elderly patients. Patients and Methods: Patients aged 75 years with advanced or recurrent NSCLC including wild-type EGFR who had previously received one or two chemotherapy regimens were enrolled in this trial. Erlotinib was initially administered at a dose of 150 mg/day orally until disease progression or unacceptable toxicities occurred. The primary endpoint was the objective response rate. Results: Forty patients were enrolled between May 2009 and January 2014.

Original language	English
Pages (from-to)	2881-2887
Number of pages	7
Journal	Anticancer research
Volume	36
Issue number	6
Publication status	Published - Jun 2016

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Yamada, K., Azuma, K., Takeshita, M., Uchino, J., Nishida, C., Suetsugu, T., Kondo, A., Harada, T., Eida, H., Kishimoto, J., Eriguchi, G., Takayama, K., Nakanishi, Y., & Sugio, K. (2016). Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802). Anticancer research, 36(6), 2881-2887.

Yamada, K, Azuma, K, Takeshita, M, Uchino, J, Nishida, C, Suetsugu, T, Kondo, A, Harada, T, Eida, H, Kishimoto, J, Eriguchi, G, Takayama, K, Nakanishi, Y & Sugio, K 2016, 'Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802)', Anticancer research, vol. 36, no. 6, pp. 2881-2887.

@article{86502cee724b4b448c9f4e69ef6ff48b,

title = "Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802)",

abstract = "Background: As the incidence of lung cancer in the elderly is increasing worldwide, there exists a need to develop a clinically effective, less toxic therapy for this patient population. Although erlotinib has shown proven effectiveness against non-small cell lung cancer (NSCLC), few studies have prospectively investigated its application to elderly patients. Patients and Methods: Patients aged 75 years with advanced or recurrent NSCLC including wild-type EGFR who had previously received one or two chemotherapy regimens were enrolled in this trial. Erlotinib was initially administered at a dose of 150 mg/day orally until disease progression or unacceptable toxicities occurred. The primary endpoint was the objective response rate. Results: Forty patients were enrolled between May 2009 and January 2014.",

author = "Kazuhiko Yamada and Koichi Azuma and Masafumi Takeshita and Junji Uchino and Chinatsu Nishida and Takayuki Suetsugu and Akira Kondo and Taishi Harada and Hirofumi Eida and Junji Kishimoto and Goki Eriguchi and Koichi Takayama and Yoichi Nakanishi and Kenji Sugio",

year = "2016",

month = jun,

language = "English",

volume = "36",

pages = "2881--2887",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6",

}

TY - JOUR

T1 - Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer

T2 - Results of the lung oncology group in kyushu (LOGiK-0802)

AU - Yamada, Kazuhiko

AU - Azuma, Koichi

AU - Takeshita, Masafumi

AU - Uchino, Junji

AU - Nishida, Chinatsu

AU - Suetsugu, Takayuki

AU - Kondo, Akira

AU - Harada, Taishi

AU - Eida, Hirofumi

AU - Kishimoto, Junji

AU - Eriguchi, Goki

AU - Takayama, Koichi

AU - Nakanishi, Yoichi

AU - Sugio, Kenji

PY - 2016/6

Y1 - 2016/6

N2 - Background: As the incidence of lung cancer in the elderly is increasing worldwide, there exists a need to develop a clinically effective, less toxic therapy for this patient population. Although erlotinib has shown proven effectiveness against non-small cell lung cancer (NSCLC), few studies have prospectively investigated its application to elderly patients. Patients and Methods: Patients aged 75 years with advanced or recurrent NSCLC including wild-type EGFR who had previously received one or two chemotherapy regimens were enrolled in this trial. Erlotinib was initially administered at a dose of 150 mg/day orally until disease progression or unacceptable toxicities occurred. The primary endpoint was the objective response rate. Results: Forty patients were enrolled between May 2009 and January 2014.

AB - Background: As the incidence of lung cancer in the elderly is increasing worldwide, there exists a need to develop a clinically effective, less toxic therapy for this patient population. Although erlotinib has shown proven effectiveness against non-small cell lung cancer (NSCLC), few studies have prospectively investigated its application to elderly patients. Patients and Methods: Patients aged 75 years with advanced or recurrent NSCLC including wild-type EGFR who had previously received one or two chemotherapy regimens were enrolled in this trial. Erlotinib was initially administered at a dose of 150 mg/day orally until disease progression or unacceptable toxicities occurred. The primary endpoint was the objective response rate. Results: Forty patients were enrolled between May 2009 and January 2014.

UR - http://www.scopus.com/inward/record.url?scp=84991576461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991576461&partnerID=8YFLogxK

M3 - Article

C2 - 27272800

AN - SCOPUS:84991576461

SN - 0250-7005

VL - 36

SP - 2881

EP - 2887

JO - Anticancer Research

JF - Anticancer Research

IS - 6

ER -

Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this